| 臺大學術典藏 |
2021-05-02T03:49:15Z |
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
|
Wu S.-G.;Yu C.-J.;Yang J.C.-H.;Jin-Yuan Shih; Wu S.-G.; Yu C.-J.; Yang J.C.-H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2021-05-02T03:49:14Z |
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
|
Wu S.-G.;Chiang C.-L.;Liu C.-Y.;Wang C.-C.;Su P.-L.;Hsia T.-C.;Jin-Yuan Shih;Chang G.-C.; Wu S.-G.; Chiang C.-L.; Liu C.-Y.; Wang C.-C.; Su P.-L.; Hsia T.-C.; JIN-YUAN SHIH; Chang G.-C. |
| 臺大學術典藏 |
2021-05-02T03:49:14Z |
Does pemetrexed work in targetable, nonsquamous non-small-cell lung cancer? A narrative review
|
Jin-Yuan Shih;Inoue A.;Cheng R.;Varea R.;Kim S.-W.; JIN-YUAN SHIH; Inoue A.; Cheng R.; Varea R.; Kim S.-W. |
| 臺大學術典藏 |
2021-05-02T03:49:14Z |
Sustained partial response to afatinib in a patient with lung adenocarcinoma harboring HER2V659E mutation
|
Chang L.-K.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2021-05-02T03:49:14Z |
Successful management of a ROS1-rearranged pulmonary pleomorphic carcinoma using serial tyrosine kinase inhibitors
|
Wu C.-W.;Yang C.-Y.;Chang Y.-L.;Jin-Yuan Shih; Wu C.-W.; Yang C.-Y.; Chang Y.-L.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2021-05-02T03:49:13Z |
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY
|
Nishio M.;Seto T.;Reck M.;Garon E.B.;Chiu C.-H.;Yoh K.;Imamura F.;Park K.;Jin-Yuan Shih;Visseren-Grul C.;Frimodt-Moller B.;Zimmermann A.;Homma G.;Enatsu S.;Nakagawa K.;Relay Study Investigators; Nishio M.; Seto T.; Reck M.; Garon E.B.; Chiu C.-H.; Yoh K.; Imamura F.; Park K.; JIN-YUAN SHIH; Visseren-Grul C.; Frimodt-Moller B.; Zimmermann A.; Homma G.; Enatsu S.; Nakagawa K.; RELAY Study Investigators |
| 臺大學術典藏 |
2021-05-02T03:49:13Z |
miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-�eB Pathway
|
Liu Y.-N.;Tsai M.-F.;Wu S.-G.;Chang T.-H.;Tsai T.-H.;Gow C.-H.;Wang H.-Y.;Jin-Yuan Shih; Liu Y.-N.; Tsai M.-F.; Wu S.-G.; Chang T.-H.; Tsai T.-H.; Gow C.-H.; Wang H.-Y.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2021-05-02T03:49:13Z |
Effect of �]-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
|
Chang C.-H.;Lee C.-H.;Ko J.-C.;Chang L.-Y.;Lee M.-C.;Zhang J.-F.;Wang J.-Y.;Jin-Yuan Shih;Yu C.-J.; Chang C.-H.; Lee C.-H.; Ko J.-C.; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; JIN-YUAN SHIH; Yu C.-J. |
| 臺大學術典藏 |
2021-05-02T03:49:12Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; JIN-YUAN SHIH; Yu C.-J. |
| 臺大學術典藏 |
2021-05-02T03:49:12Z |
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
|
Lu S.; JIN-YUAN SHIH; Jang T.-W.; Liam C.-K.; Yu Y. |
| 臺大學術典藏 |
2021-05-02T03:49:12Z |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
|
Chang G.-C.; Lam D.C.-L.; Tsai C.-M.; Chen Y.-M.; JIN-YUAN SHIH; Aggarwal S.; Wang S.; Kim S.-W.; Kim Y.-C.; Wahid I.; Li R.; Lim D.W.-T.; Sriuranpong V.; Chan R.T.-T.; Lorence R.M.; Carriere P.; Raabe C.; Cseh A.; Park K. |
| 臺大學術典藏 |
2021-05-02T03:49:11Z |
Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel
|
Huang J.-W.; Kuo C.-H.; Kuo H.-C.; JIN-YUAN SHIH; Tsai T.-W.; Chang L.-C. |
| 臺大學術典藏 |
2021-05-02T03:49:11Z |
Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1
|
Chung K.-P.; Huang Y.-L.; Chen Y.-J.; Juan Y.-H.; Hsu C.-L.; Nakahira K.; Huang Y.-T.; Lin M.-W.; Wu S.-G.; JIN-YUAN SHIH; Chang Y.-L.; Yu C.-J. |
| 臺大學術典藏 |
2021-05-02T03:49:10Z |
Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer
|
Hsu C.-L.; Tsai T.-H.; Huang C.-K.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Ruan S.-Y.; Chen K.-Y.; JIN-YUAN SHIH; Yang P.-C. |
| 臺大學術典藏 |
2021-05-02T03:49:10Z |
Differences in Fatty Acid Oxidation between Nab-Paclitaxel- And Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics
|
Huang J.-W.; Kuo C.-H.; Kuo H.-C.; JIN-YUAN SHIH; Tsai T.-W.; Chang L.-C. |
| 臺大學術典藏 |
2021-05-02T03:49:09Z |
Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer
|
Huang Y.-S.; Chen J.L.-Y.; Chen H.-M.; Yeh L.-H.; JIN-YUAN SHIH; Yen R.-F.; Chang Y.-C. |
| 臺大學術典藏 |
2021-04-21T23:30:40Z |
Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel
|
Huang, Jhih Wei; CHING-HUA KUO; Kuo, Han Chun; JIN-YUAN SHIH; Tsai, Teng Wen; LIN-CHAU CHANG |
| 臺大學術典藏 |
2021-03-11T08:34:21Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; Min-Shu Hsieh; MENG-RUI LEE; LI-TA KENG; JEN-CHANG KO; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-03-11T08:34:18Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.;Jen-Chang Ko;Yang J.C.-H.;Shih J.-Y.; SHENG-KAI LIANG; JEN-CHANG KO; James Chih-Hsin Yang; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-02-08T08:05:08Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Jen-Chung Ko;Sheng-Kai Liang;Li-Ta Keng;Chia-Hao Chang;Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu; JEN-CHUNG KO; SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu |
| 臺大學術典藏 |
2021-02-02T09:21:39Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen, Yueh Feng; MENG-RUI LEE; Yang, Ching Yao; JANN-YUAN WANG; JEN-CHUNG KO; JIN-YUAN SHIH; CHONG-JEN YU |
| 臺大學術典藏 |
2021-01-18T09:12:07Z |
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY
|
Nishio, Makoto; Seto, Takashi; Reck, Martin; Garon, Edward B.; Chiu, Chao Hua; Yoh, Kiyotaka; Imamura, Fumio; Park, Keunchil; JIN-YUAN SHIH; Visseren-Grul, Carla; Frimodt-Moller, Bente; Zimmermann, Annamaria; Homma, Gosuke; Enatsu, Sotaro; Nakagawa, Kazuhiko |
| 臺大學術典藏 |
2021-01-08T02:56:46Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
Yen-Fu Chen; I-Chun Chen; Jui-Chen Cheng; SHENG-KAI LIANG; Shu-Yung Lin; Li-Ta Keng;Chung K.-P.;Lin S.-Y.;Liang S.-K.;Cheng J.-C.;Chen I.-C.;Chen Y.-F.;Chang H.-T.;Hsu C.-L.;Jerng J.-S.;Wang H.-C.;Kuo P.-H.;Wu H.-D.;Shih J.-Y.;Yu C.-J.; LI-TA KENG; Kuei-Pin Chung; Hou-Tai Chang; Chia-Lin Hsu; Jih-Shuin Jerng; Hao-Chien Wang; Ping-Hung Kuo; Huey-Dong Wu; Jin-Yuan Shih; Chong-Jen Yu |
| 臺大學術典藏 |
2020-08-13T06:34:14Z |
Elevated serum levels of mucin-associated antigen in patients with acute respiratory distress syndrome
|
Jin-Yuan Shih;Yang S.-C.;Yu C.-J.;Wu H.-D.;Liaw Y.-S.;Wu R.;Yang P.-C.; JIN-YUAN SHIH; Yang S.-C.; Yu C.-J.; Wu H.-D.; Liaw Y.-S.; Wu R.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:34:14Z |
Echogenic floating spherules as a sonographic sign of cystic teratoma of mediastinum: Correlation with CT and pathologic findings
|
Wang H.-C.; JIN-YUAN SHIH; Jin-Yuan Shih;Wang H.-C.;Chang Y.-L.;Chang Y.-C.;Lee Y.-C.;Yang P.-C.; Chang Y.-L.; Chang Y.-C.; Lee Y.-C.; Yang P.-C. |
